No Data
No Data
Meditrina Welcomes Senior Vice President of Global Sales to Lead Expansion Efforts and Manage Rapid Growth
Hologic's (NASDAQ:HOLX) Soft Earnings Don't Show The Whole Picture
Shareholders appeared unconcerned with Hologic, Inc.'s (NASDAQ:HOLX) lackluster earnings report last week. We think that the softer headline numbers might be getting counterbalanced by some positive
Hologic Is Maintained at Buy by Argus Research
Hologic Is Maintained at Buy by Argus Research
Hologic Price Target Raised to $95.00/Share From $89.00 by Argus Research
Hologic Price Target Raised to $95.00/Share From $89.00 by Argus Research
Argus Adjusts Price Target on Hologic to $95 From $89
Hologic (HOLX) has an average rating of outperform and price targets ranging from $70 to $95, according to analysts polled by Capital IQ.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Hologic (HOLX) and Arbutus Biopharma (ABUS)